OncoSec Medical Announces $13.6 Million Registered Direct Offering

SAN DIEGO, June 3, 2015 /PRNewswire/  OncoSec Medical Inc. ( OncoSec ) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that it has entered into definitive agreements with dedicated healthcare institutional investors to purchase approximately $13.6 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 2,469,091 shares of its common stock at a price of $5.50 per share. The gross proceeds of the offering are approximately $13.6 million. Net proceeds, after deducting the placement agent s fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $12.6 million. OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses. H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction. Maxim Group LLC and Noble Life S


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: